NewsPronto

 
The Times


.

ACN Newswire

Read more press releases from ACN Newswire here

Nanobiotix Announces Submission for First Market Approval of Lead Product NBTXR3 in Europe

  • Written by ACN Newswire

image

- CE Mark filing based on current level of scientific and clinical evidence- Phase II/III clinical trial in Soft Tissue Sarcoma progressing well towards interim data readout with almost 2/3 of the patients randomized

Paris, France and Cambridge, Massachusetts, USA, Sep 14, 2016 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205),...

Read more: Nanobiotix Announces Submission for First Market Approval of Lead Product NBTXR3 in Europe